Lecture 9 & 10 - trombositopenia PSPDG
Thrombocytopenia Overview
Defined as a low platelet count in the blood.
Can result in increased bleeding and various clinical manifestations.
Platelet Biochemistry
A. Platelet Production and Structure
Production: Platelets originate from megakaryocytes in bone marrow through pseudopod formation and septation.
Life Span: 5-7 days in circulation.
Size: 2-3 microns in diameter.
Structure: Lack a nucleus, but contain mitochondria and messenger RNA.
Granules: Two types visible under electron microscope; functionally three types:
Dense granules
Alpha granules
Lysosomal granules
Clinical Features of Platelet Disorders
Hemorrhage Risk: Increases when platelet count falls below 50,000.
Sites of Bleeding:
Cutaneous (petechiae, purpura, ecchymosis, venipuncture sites)
Mucosal (epistaxis, menometrorrhagia, hemorrhagic bullae, gastrointestinal bleeding)
Central nervous system (CNS)
Clinical Manifestations Associated with Falling Platelet Counts
Platelet Count per Microliter | Clinical Manifestations |
|---|---|
50,000-20,000 | Increased bleeding during surgery and trauma |
<20,000 | Increased risk of spontaneous hemorrhage |
<10,000 | Increased risk of spontaneous intracerebral hemorrhage |
Quantitative Platelet Disorders
Thrombocytopenia: Defined as decreased platelet count caused by various factors.
Causes of Thrombocytopenia by Decreased Platelet Production
Primary Bone Marrow Disorders:
Aplastic anemia, Fanconi anemia, Leukemia, Myelodysplasia
Bone Marrow Invasion:
Metastatic cancer, Myelofibrosis, infections (e.g. tuberculosis)
Bone Marrow Injury:
Chemicals (e.g. benzene), drugs (e.g. chemotherapy agents), radiation, infection
Nutritional Disorders:
Vitamin B12, Folate, Copper deficiencies
Hereditary Syndromes:
Hypomegakaryocytic thrombocytopenia, ineffective platelet production syndromes (e.g., May-Hegglin anomaly)
Increased Destruction of Platelets Causes
Immune-Mediated Thrombocytopenia:
Autoimmune conditions (e.g., ITP), Alloimmune thrombocytopenia, Drug-induced immune thrombocytopenia (e.g. Heparin-induced thrombocytopenia)
Non-Immune-Mediated Thrombocytopenia
Conditions:
Disseminated Intravascular Coagulation (DIC)
Thrombotic Thrombocytopenic Purpura (TTP)
Hemolytic Uremic Syndrome (HUS)
Differential Diagnosis of Acquired Destructive Thrombocytopenias
Condition | PT | aPTT | Platelet Count | Schistocytes |
|---|---|---|---|---|
DIC | Increase | Increased | Decreased | Sometimes present |
ITP | Normal | Normal | Decreased | None |
TTP | Normal | Normal | Decreased | Present |
HUS | Normal | Normal | Decreased | Present |
Clinical Thresholds for Surgery
Neurosurgery or ocular surgery: Platelet count should be >100,000/microL
Major surgeries: Platelet count should be >50,000/microL
Endoscopic procedures: 50,000/microL for therapeutic; 20,000/microL for low-risk diagnostic
Central line placements: <20,000/microL
Dental Alerts:
Routine treatment contraindicated if platelet count <50,000/mm3
Platelet count must be >75,000/mm3 for outpatient surgery, ideally >100,000/mm3 for major surgical procedures in OR.